timothy sykes logo
SLDB Jumps As Analyst Hikes Price Target To $25 Thumbnail
G Google News

SLDB Jumps As Analyst Hikes Price Target To $25

TIM SYKES•UPDATED JUN. 21, 2026, 10:08 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Solid Biosciences Inc. stocks have been trading up by 14.29 percent on optimism surrounding its latest gene therapy developments.

What Traders Need To Know

  • H.C. Wainwright raised its price target on Solid Biosciences from $20 to $25 and reiterated a Buy rating after what it described as encouraging updates on the company’s SGT-212 gene therapy program for Friedreich’s ataxia.
  • The stock has pushed from roughly $7.05 to above $8.30 in recent sessions, showing strong short-term momentum.
  • Intraday action shows a surge from the mid-$7s into the low $8s on heavy buying, confirming demand around the analyst call.
  • Solid Biosciences granted 6,580 restricted stock units to a newly hired employee under its 2024 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The newly granted restricted stock units will vest over four years, contingent on the employee’s continued service with Solid Biosciences.

Candlestick Chart

Weekly Update Jun 15 – Jun 19, 2026: On Sunday, June 21, 2026 Solid Biosciences Inc. stock [NASDAQ: SLDB] is trending up by 14.29%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Solid Biosciences (SLDB) remains a pre-revenue, early‑clinical gene therapy name with highly speculative fundamentals. Revenues have effectively gone to zero over 3–5 years, and return metrics are deeply negative (ROE ~‑57%, ROA ~‑50%), reflecting heavy R&D spend (Q1 R&D ~$46M vs G&A ~$11M). However, balance sheet strength is a clear positive: ~$298M cash, minimal debt (total debt/equity 0.06), current ratio 13.1, and enterprise value (~$146M) well below cash, implying the market heavily discounts pipeline value and future dilution risk.

Technically, SLDB shows an emerging short‑term upside breakout. The weekly tape from ~7.05–7.36 followed by a sharp push to 8.33–8.50 and a close at ~8.35 signals strong demand after consolidation, likely on elevated volume versus prior days. The dominant near‑term trend is up, with 8.00 as immediate support and 7.00 as a must‑hold swing level. A tactical trading plan favors buying pullbacks toward 8.00 with a stop below 7.00 and an initial target near 9.50.

Recent news is clearly constructive: H.C. Wainwright lifting its target from $20 to $25 and reiterating Buy, citing encouraging SGT‑212 Friedreich’s ataxia data, materially upgrades sentiment versus broader biotech, where many small caps trade on financing fear rather than data. The inducement RSU grant is routine. Versus Healthcare and Biotechnology benchmarks, SLDB offers higher binary risk but superior cash runway. Key levels: support 8.00, major support 7.00, resistance 9.50 then 12.00. Verdict: risk‑tolerant Buy.

More Breaking News

Quick Financial Overview

Solid Biosciences Inc. (SLDB) is trading in an active upswing, with weekly data showing a move from about $7.05 to roughly $8.35 in a few days. That is a meaningful percentage push in a short window, and it lines up with the H.C. Wainwright price target increase to $25 and reiterated Buy rating. Intraday, the stock has run from around $7.58 to near $8.33, with a wide range between $7.49 and $8.42, which tells traders volatility is elevated and range expansion is in play.

On the fundamentals, SLDB is still a development-stage biotech with deep losses. The latest quarterly income statement shows net income of about -$56.7M and basic EPS of -$0.52, driven mainly by roughly $46.1M in research and development expense. Profitability ratios confirm this, with a pretax margin near -3,413.8% and very negative returns on assets and equity, which is typical for an early-stage gene therapy name but still a risk factor.

The balance sheet is where SLDB looks stronger. Cash and cash equivalents stand around $297.1M, and total cash, equivalents, and short-term investments are roughly $380.7M against total liabilities of about $48.8M. Current ratio near 13.1 and very low debt-to-equity (around 0.06) suggest Solid Biosciences has runway to fund its SGT-212 program. Valuation-wise, with book value per share about 3.8 and price-to-book around 1.91, traders are paying a premium to book but not an extreme one for a gene therapy story.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading SLDB

Millionaire's
POV on SLDB

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”